Tolebrutinib

Tolebrutinib

  • Also known as: SAR442168
  • Pharmaceutical Company: Sanofi
  • Route and Dose of Administration: Oral (once daily)
  • Type: Immunomodulator
  • Emerging Treatment for: Relapsing Multiple Sclerosis (RMS); Non-relapsing Secondary Progressive Multiple Sclerosis (nrSPMS); Primary Progressive Multiple Sclerosis (PPMS)
  • Status: Completed Phase III clinical trials


How it works
Tolebrutinib selectively inhibits the protein, Bruton’s tyrosine kinase or BTK, to reduce the activation of B cells that contribute to brain and spinal cord inflammation in MS. Tolebrutinib has also been proposed to modulate a specific immune cell called microglia, an immune cell of the central nervous system linked to MS progression.  In the Phase III trial, tolebrutinib was shown to slow down disability progression in people with non-relapsing secondary progressive MS. 

Relapsing MS Trials
Phase III Trial: GEMINI 1 and GEMINI 2  

Progressive MS Trials
Phase III Trial: HERCULES

Phase III Trial: PERSEUS